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A B S T R A C T
Poorly formulated probiotic supplements intended for oral administration often fail to protect bacteria from the
challenges of human digestion, meaning bacteria do not reach the small intestine in a viable state. As a result, the
ability of probiotics to inﬂuence the human gut microbiota has not been proven. Here we show how (i) con-
sidered formulation of an aqueous probiotic suspension can facilitate delivery of viable probiotic bacteria to the
gut and (ii) quantitate the eﬀect of colonisation and proliferation of speciﬁc probiotic species on the human gut
microbiota, using an in-vitro gut model. Our data revealed immediate colonisation and growth of three probiotic
species in the luminal and mucosal compartments of the proximal and distal colon, and growth of a fourth
species in the luminal proximal colon, leading to higher proximal and distal colonic lactate concentrations. The
lactate stimulated growth of lactate-consuming bacteria, altering the bacterial diversity of the microbiota and
resulting in increased short-chain fatty acid production, especially butyrate. Additionally, an im-
munomodulatory eﬀect of the probiotics was seen; production of anti-inﬂammatory cytokines (IL-6 and IL-10)
was increased and production of inﬂammatory chemokines (MCP-1, CXCL 10 and IL-8.) was reduced. The results
indicate that the probiotic species alone do not result in a clinical eﬀect; rather, they facilitate modulation of the
gut microbiota composition and metabolic activity thereby inﬂuencing the immune response.
1. Introduction
The global market for products containing probiotic species, “live
microorganisms that, when administered in adequate amounts, confer a
health beneﬁt on the host” (Hill et al., 2014) is large (predicted to reach
over $46 bn by 2020 (O’Toole et al., 2017)). Poorly formulated pro-
biotic supplements intended for oral administration often fail to protect
bacteria from the challenges of human digestion, meaning bacteria do
not reach the small intestine in a viable state and that any feeling of
improved health often reduces to a placebo eﬀect. Further, the ability of
probiotic species to inﬂuence established gut microbiota has not been
proven. As a result, healthcare professionals and the general public
often view the use of probiotics to alleviate clinical symptoms with
scepticism.
The main process occurring in the human colon is the fermentation
of non-digestible carbohydrates by the resident colonic microbiota
yielding various metabolic end-products (primarily the short-chain
fatty acids (SCFA) acetate, propionate and butyrate, (Tremaroli and
Bäckhed, 2012)). Lactate, which is not an SCFA, is also produced as a
result of fermentation but does not accumulate in the colon because it is
a substrate for several SCFA-producing bacteria, such as Eubacterium
hallii and Anaerostipes caccae or Megasphaera spp., resulting in the
production of butyrate or propionate, respectively (Louis et al., 2014;
Flint et al., 2015). SCFAs are important for general gut health (Ríos-
Covían et al., 2016) as an energy source for peripheral tissues (acetate
and propionate) and colonocytes (butyrate) (Hamer et al., 2008), but
they also inﬂuence inﬂammation, vasodilation, gut motility and wound
healing (Bergman, 1990). For instance, dysbiosis in ulcerative colitis
(UC) patients has been linked to a reduction in butyrate-producing
species (Machiels et al., 2014), reduced levels of propionate-producing
species have been linked with asthma in children (Arrieta et al., 2015)
while broad changes in the gut microbiota have been linked with
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irritable bowel syndrome (IBS) (Rajilic-Stojanovic et al., 2011; Simren
et al., 2013; Jalanka-Tuovinen et al., 2014; Distrutti et al., 2016) and
irritable bowel disease (IBD) (Matsuoka and Kanai 2015). It has also
been proposed that butyrate produced from a high-ﬁber diet can im-
prove brain health (Bourassa et al., 2016) and function (Stiling et al.,
2016). Ensuring the gut microbiota is optimally balanced and so pro-
ducing high SCFA, especially butyrate, levels is therefore an important
focus in maintaining and improving general health and wellbeing.
The introduction and integration of probiotic species to the gut
microbiota has the potential to reduce dysbiosis and/or improve gen-
eral health by inﬂuencing a range of factors (for instance, extent of
bacterial diversity, production of SCFAs and/or colonisation of the
mucosal layer/reduction in inﬂammation response) but achieving
clinical eﬃcacy requires formulation of bacteria in a nutritional sup-
plement in a way that oﬀers protection from the challenges of oral
delivery (Coghetto et al., 2016); primarily, these challenges result from
exposure of bacteria to gastrointestinal ﬂuids (the low pH of stomach
acid and the bile salt/pancreatic enzyme concentrations in the small
intestine). Probiotics are often added to dairy products or formulated in
freeze-dried capsules or tablets, but in-vitro testing has shown many
probiotic supplements cannot protect bacteria against stomach acid pH
(Fredua-Agyeman and Gaisford, 2015). Alternative formulation strate-
gies, such as microencapsulation of bacteria (Mirtic et al, 2018), enteric
coating (Dodoo et al., 2017) or gelation of emulsions (Picone et al.,
2017) show eﬃcacy in-vitro but are technologies that are not ready for
commercial use. It is also necessary that probiotic bacteria, once they
reach the gut, are able to inﬁltrate, colonise and proliferate in the lu-
minal and mucosal compartments. A recent in-vivo study on an 11-strain
probiotic suggested that mucosal colonisation by the bacteria was a
challenge and that any eﬀect on the gut microbiota was at best transient
(Zmora et al., 2018).
Recently, a 4-strain aqueous probiotic supplement (SymproveTM,
containing Lactobacillus acidophilus NCIMB 30175, Lactobacillus plan-
tarum NCIMB 30173, Lactobacillus rhamnosus NCIMB 30174 and
Enterococcus faecium NCIMB 30176) has been shown to reduce clinical
symptom severity scores in IBS (Sisson et al., 2014) and to reduce ab-
dominal pain scores and signiﬁcantly reduce constipation, diarrhoea
and mucorrhoea in diverticular disease (Kvasnovsky et al., 2017).
Symprove also showed a high degree of gastric acid tolerance during in-
vitro testing (Fredua-Agyeman and Gaisford, 2015) and anti-pathogenic
activity against Clostridium diﬃcile (Fredua-Agyeman et al., 2017).
Understanding, and more importantly quantifying, the eﬀect of pro-
biotics in modulating the human gut microbiota is very challenging in-
vivo, because of the complexity in sampling and analysing the micro-
biota, its metabolic products and its inﬂuence on immune response in
real-time. However, recently developed in-vitro gut models, which
contain viable microbiota from healthy human donors and that have
both luminal and mucosal compartments, allow the complex interac-
tions between probiotics, commensal gut bacteria and the gut wall to be
monitored and quantiﬁed. Hence, the principal aim of this work was to
assess the ability of the probiotic bacteria in Symprove to inﬂuence
three healthy human gut microbiotas using an in-vitro gut model (Si-
mulator of the Human Intestinal Microbial Ecosystem, equipped with
mucosal compartments (M-SHIME®)); the eﬀects on bacterial diversity,
SCFA production and inﬂammatory markers, following dosing with
Symprove over a three-week period, were quantiﬁed.
2. Materials and methods
2.1. M-SHIME® Testing
SymproveTM was obtained from Symprove Ltd and used as received.
Experiments were performed using the M-SHIME® system. Brieﬂy, the
system comprised four reactors vessels (V). The ﬁrst two reactors are of
the ﬁll-and-draw principle and simulate the initial stages in food uptake
and digestion. Peristaltic pumps add feed (140mL, 3x per day) and
pancreatic/bile juice (60mL, 3× per day) to the stomach (V1) and
small intestine (V2) respectively and empty each reactor after deﬁned
time intervals. The remaining 2 reactors simulate the conditions of the
proximal (V3) and distal (V4) colon. Colon vessels are constantly
stirred, retain a ﬁxed volume (PC=500mL; DC=800mL) and their
pH is constant (PC= 5.6–5.9; DC=6.6–6.9). The retention time of
media in each vessel is selected to mimic human in-vivo conditions
(Possemiers et al 2004). The colon reactors were inoculated with fecal
microbiota from healthy human donors (consuming a Western-style
diet) and the microbial community was allowed to stabilise over a 2-
week period. The microbiota was then maintained for a further 2-week
control period. During this period, the baseline microbial community
composition and activity were recorded. Three donors were used in this
study to address inter-individual variability. A three-week treatment
phase then commenced; Symprove was added to V1 and was progressed
through V2 prior to being fed to the colonic microbiota. One set of V1-
V2 vessels was used to minimise variability of the feed material,
meaning the feed arriving in the proximal colon vessels was the same
for all donors. Mucin-covered microcosms were added to all colonic
vessels, enabling maintenance of not only a luminal microbiota but also
a speciﬁc mucosal microbiota in the colonic regions (Van den Abbeele
et al., 2012, 2013).
2.2. Quantiﬁcation of viable and non-viable bacteria by ﬂow cytometry
Samples were collected from diﬀerent stages at various time inter-
vals in V1 and V2 to investigate upper gastro-intestinal survival of the
probiotic species. A ten-fold dilution series was initially prepared in
phosphate buﬀered saline. Assessment of the viable and non-viable
populations of the bacteria was done by staining the appropriate dilu-
tions with SYTO 24 and propidium iodide. Samples were analyzed on a
BDFacs verse, using a high ﬂow rate. Bacterial cells were separated
from medium debris and signal noise by applying a threshold level of
200 on the SYTO channel. Proper parent and daughter gates were set to
determine all populations. Results are reported as average log
(counts)± sd of the three independent biological replicates.
2.3. Measurement of SCFA/BCFA, lactate and ammonium
SCFA levels, including acetate, propionate, butyrate and branched
SCFA (isobutyrate, isovalerate and isocaproate) were monitored as
described by De Weirdt et al. (2010). Lactate quantiﬁcation was per-
formed using a commercially available enzymatic assay kit (R-Bio-
pharm, Darmstadt, Germany) according to the manufacturer’s instruc-
tions. Ammonium analysis was performed as previously described by
Van de Wiele et al (2004). Brieﬂy, the ammonium in the liquid samples
was quantiﬁed by initially performing a steam distillation. Subse-
quently, the ammonium in the distillate was determined titrimetrically
with HCl.
2.4. Microbial community analysis
During the reference and treatment periods, samples for microbial
community analysis were collected once per week from each colon
vessel. DNA was isolated using the protocol as described by Vilchez-
Vargas et al. (2013), starting from pelleted cells originating from 1mL
luminal or 0.1 g mucus samples. Numbers of the probiotic species were
determined with a qPCR protocol, using the species-speciﬁc primers
and probes listed in Table S1. Although the primers are species but not
strain speciﬁc, the microbiota were established over a 4-week period
prior to dosing with Symprove, so any increase in the numbers of
bacterial species during the treatment period is a result of probiotic
treatment, meaning strain speciﬁc primers were not required. The qPCR
was performed on a QuantStudio 5 Real-Time PCR system (Applied
Biosystems, Foster City, CA USA). Each sample was analysed in tripli-
cate. Results are reported as average log(copies/mL) for the luminal
F. Moens et al. International Journal of Pharmaceutics 555 (2019) 1–10
2
samples and as average log(copies/g) for the mucosal samples ± sd of
the three technical replicates.
The microbiota proﬁling of each colon compartment was estab-
lished by 16S-targeted sequencing analysis. The 16S rRNA gene V3-V4
hypervariable regions were ampliﬁed by PCR using primers 341F (5′-
CCT ACG GGN GGC WGC AG -3′) and 785Rmod (5′-GAC TAC HVG GGT
ATC TAA KCC-3′), with the reverse primer being adapted from
Klindworth et al. (2013) to increase coverage. Quality control PCR was
conducted using Taq DNA Polymerase with the Fermentas PCR Kit
according to the manufacturers’ instructions (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). The obtained PCR product was run along the DNA
extract on a 2% agarose gel for 30min at 100 V. 10 µl of the original
genomic DNA extract was sent out to LGC genomics GmbH (Germany)
for library preparation and sequencing on an Illumina Miseq platform
with v3 chemistry with the primers mentioned above.
2.5. Caco-2/THP1-blueTM co-culture model
The co-culture experiment was performed as previously described
(Daguet et al., 2013). Brieﬂy, Caco-2 cells (HTB-37; American Type
Culture Collection) were seeded in 24-well semi-permeable inserts
(0.4 μm pore size) at a density of 1 x 105 cells/insert. Caco-2 mono-
layers were cultured for 14 days, with three changes of medium per
week, until a functional monolayer with a transepithelial electrical re-
sistance (TEER) of more than 300Ω cm2 was obtained (measured with a
Millicell ERS-2 epithelial volt-ohm meter, Millipore). Cells were main-
tained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) containing glu-
cose (25mM) and glutamine (4mM), supplemented with HEPES
(10mM) and heat-inactivated fetal bovine serum (HI-FBS, 20% v/v).
THP1-BlueTM cells (InvivoGen) were seeded in 24-well plates at a
density of 5 × 105 cells/well and treated with phorbol 12-myristate 13-
acetate (PMA) for 48 h and maintained in Roswell Park Memorial
Institute (RPMI) 1640 medium containing glucose (11mM) and gluta-
mine (2mM), supplemented with HEPES (10mM), sodium pyruvate
(1 mM) and HI-FBS (10% v/v).
Before setting up the co-culture, the TEER of the Caco-2 monolayer
was measured (the TEER of an empty insert was subtracted from all
readings). Caco-2 bearing inserts were then placed on top of the PMA-
diﬀerentiated THP1-blueTM cells. The apical compartment (containing
Caco-2 cells) was ﬁlled with sterile-ﬁltered (0.22 μm) colonic SHIME
media (diluted 1:5 v/v in Caco-2 complete medium). Cells were treated
apically with sodium butyrate (Sigma-Aldrich) as a positive control.
The basolateral compartment (containing THP1-blueTM cells) was ﬁlled
with Caco-2 complete medium. Cells were treated for 24 h, after which
the TEER was measured. The basolateral supernatant was then dis-
carded and cells were stimulated on the basolateral side with Caco-2
complete medium containing ultrapure lipopolysaccharide (LPS, E. coli
K12, InvivoGen). Cells were also stimulated at the basolateral side with
LPS in combination with hydrocortisone (HC, Sigma-Aldrich) and
medium without LPS as controls. After LPS stimulation (6 h) the baso-
lateral supernatants were collected for cytokine measurement (human
IL-1β, IL-6, IL-8, IL-10, CXCL10 and MCP-1) by Luminex® multiplex
(Aﬀymetrix-eBioscience) and for NF-κB activity. All measurements
were performed in triplicate and cells were incubated at 37 °C in a
humidiﬁed atmosphere of air/CO2 (95:5 v/v).
3. Results
Fecal samples were obtained from three healthy adult donors and
used to establish three discrete gut models, each with a representative
human microbiota. Following a two-week stabilization period and a
further two-week control period, during which the donor microbiotas
were established and vibrant, Symprove was dosed daily over a three-
week period into the M-SHIME® gut simulator. This exposed the bac-
teria to stomach acid conditions for 45min (in-vivo MRI imaging has
shown that the half-emptying time for pure water (240mL) in humans
is 13 ± 1min, (Mudie et al., 2014)) after which they transferred to
small intestinal ﬂuid for 180min. The data in Fig. 1 show the total and
viable cell counts following exposure to these phases; 99.3% of bacteria
remained viable during this challenge. This indicates that the aqueous
formulation of Symprove protected the bacteria against the low gastric
pH and the high concentrations of bile salts present in the small in-
testine, consistent with the results of earlier in-vitro acid-tolerance
testing (Fredua-Agyeman and Gaisford, 2015). Following this period of
exposure to gastric and small intestinal ﬂuids, bacteria were transferred
to the established microbiotas from three healthy adult donors.
Fig. 2 shows how the probiotic species colonised the luminal and
mucosal compartments of the proximal and distal colons. L. acidophilus
was not detected in the control samples, indicating it is not natively
present in the human microbiota, and only appeared at a detectable
level in the proximal colon after two weeks. It did not colonise the
lumen of the distal colon, nor the mucosal compartments of the prox-
imal and distal colons, during the dosing period. This probably reﬂects
the fact that during production of Symprove, L. acidophilus is added as a
facilitator to aid the growth of L. rhamnosus and in the ﬁnal product it is
not present at greater than 104 copies/mL. L. rhamnosus was also not
detected in the control samples, but immediately colonised the luminal
compartments upon dosing with Symprove, reaching ca. 106 copies/mL
in the proximal colon and ca. 107 copies/mL in the distal colon after
1 week. It remained detectable at these concentrations throughout the
rest of the dosing period. It also immediately colonised the mucosal
compartment of the proximal colon, reaching 104 copies/g but was
never detected in the mucosal compartment of the distal colon. L.
plantarum was sporadically detected in the lumen of the proximal colon
during the control period but immediately colonised the luminal and
mucosal compartments of the proximal (108 copies/mL luminal and 105
copies/g mucosal) and distal (107 copies/mL luminal and 105 copies/g
mucosal) colons. E. faecium was abundantly present in all compart-
ments during the control period, but its numbers increased upon dosing
with Symprove, reaching ca. 108 copies/mL in the luminal and ca. 106
copies/g in the mucosal compartments.
Fig. 3 reports the lactate and SCFA concentrations in the proximal
and distal colon before and during dosing with Symprove. Concentra-
tions of lactate rose after dosing with Symprove, and increased with
continued dosing. Lactate is a major by-product of carbohydrate fer-
mentation by lactobacilli (Moens et al., 2017) and biﬁdobacteria (De
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Fig. 1. Total bacterial counts (left) and total viable cell counts (right), de-
termined with ﬂow cytometry, for Symprove bacteria upon addition to stomach
juice (St0), after 45min in stomach juice (St45) and after 180min in small in-
testinal ﬂuid (SIt180).
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species, such as Veillonella and Megasphaera (Reichardt et al., 2014),
and butyrate-producing species, such as A. caccae and E. hallii (Duncan
et al., 2004a). Thus, the measured lactate concentrations will always be
the net diﬀerence between production and consumption.
The SCFA data show that acetate is the most abundant (50.9%
across the proximal and distal colon), followed by butyrate and pro-
pionate. This correlates with in-vivo data showing acetate comprises
more than half the total SCFA detected in human faeces (Louis et al.,
2007) and arises because numerous bacterial groups (including biﬁ-
dobacteria (De Vuyst et al., 2014), bacteroidetes (Macy et al., 1978)
and acetogenic bacteria (Ragsdale and Pierce 2008) produce it as a by-
product of saccharolytic fermentation. Acetate is itself a substrate for
many butyrate-producing species (such as Faecalibacterium prausnitzii
and Roseburia spp. (Duncan et al., 2004b) and is an essential co-sub-
strate that needs to be consumed to complete butyrate synthesis from
lactate or carbohydrate (Duncan et al., 2002). Thus, as in the case of
lactate, the concentration of acetate is always the net diﬀerence be-
tween production and consumption. Propionate levels were variable in
the donor microbiotas and were not signiﬁcantly altered during dosing
with Symprove. Butyrate concentrations were signiﬁcantly increased,
relative to the control, in both the proximal and distal colons. Unlike
acetate and lactate, butyrate is the end product of fermentation and so
it is not consumed in the in-vitro gut model, but in-vivo butyrate is a
major energy source for colonocytes (which utilise up to 90% of
butyrate (Hamer et al., 2008) and high butyrate concentrations are
generally linked with improved health (Tan et al., 2014; Ríos-Covían
et al., 2016).
Once carbohydrate is depleted the colonic microbiota will switch
from saccharolytic fermentation to proteolytic fermentation of protein,
resulting in production of ammonium, branched-chain fatty acids
(BCFA, typically isobutyrate, 2-methylbutyrate and isovalerate) and
various amines, phenols/indoles and sulphides; these compounds gen-
erally impair colon health and so their presence is undesirable (Scott
et al., 2013). Fig. 4 shows that dosing with Symprove actually reduced
both BCFA and ammonium levels compared with the control.
Fig. 5 shows the diversity of the gut microbiota, in terms of the six
major phyla, for the three donors during the control and dosing periods
(familial detail of operational taxonomic units (OTU) within phyla are
given in Tables S2 and S3). In general, dosing with Symprove enriched
the proximal and distal luminal levels, and the distal mucosal level, of
Actinobacteria of donors 1 and 2 at the expense of Bacteroidetes. In
particular, Biﬁdobacterium pseudocatenulatum was increased in donors 1
and 2 and Biﬁdobacterium adolescentis was increased in donor 3, mainly
at the expense of Biﬁdobacterium longum. For donors 2 and 3 there was
also a marked increase in the mucosal numbers of Biﬁdobacterium bi-
ﬁdum. Biﬁdobacteria belong to the Actinobacteria, so the increase in
this phylum could explain the higher acetate concentrations but also
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Fig. 2. Average log(copies/mL)± sd (lumen; n=3) or average log(copies/g)± sd (mucus; n= 3) for the Symprove bacteria in the luminal and mucosal com-
partments of the proximal and distal colon of the three donors for the donor control samples (C) and following 1week (T1), 2 weeks (T2) and 3weeks (T3) daily dosing
with Symprove. L. acidophilus (top left), L. plantarum (top right), L. rhamnosus (bottom left) and E. faecium (bottom right).
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feeding interactions with butyrate-producing bacteria discussed above,
while the reduction in Bacteroidaceae could explain the low propionate
concentrations. Luminal levels of Firmicutes increased in the proximal
colon of donors 1 and 2 and in the distal colon of all three donors. At
OTU level, the main changes were attributed to OTU 33 (L. plantarum)
and OTU 125 (L. rhamnosus), reﬂecting successful colonisation by the
probiotic bacteria in Symprove. Ruminococcaceae numbers increased in
all three donors, with OTU 64 (F. prausnitzii) numbers raised in donor 2
(and the mucosal compartments of all donors) and OTU 29 (Sub-
doligranulum spp.) in donors 1 and 3. Interestingly, Lachnospiraceae, a
strongly butyrate-producing family, were suppressed in the mucosal
compartments of all donors. Veillonellaceae numbers were increased for
all donors but particularly for donor 2 (OTU 1,Megasphaera spp.). Many
butyrate-producing bacteria belong to the Firmicutes, so the increase in
proportion of this phylum also correlates with the raised butyrate levels
discussed above. Other lactate-producing families that were enriched
following dosing with Symprove included Enterococcaceae in the lu-
minal and mucosal proximal colon and luminal distal colon of donors 1
and 3, reﬂective of the wide colonisation by E. faecium, and Strepto-
coccaceae in all compartments of all donors; these increases are man-
ifest in the general increase in the Actinobacteria and Firmicutes phyla.
Synergistetes colonised the distal colon of donors 2 and 3 and their
numbers increased after dosing with Symprove.
A Caco-2-THP1-BlueTM co-culture in-vitro model was used to assess
the inﬂammatory response of SHIME samples (control and after dosing
with Symprove). Following dosing with Symprove, no reduction in
transepithelial electrical resistance (TEER) was seen in the cell culture
model (Table S4), indicating integrity of the cell wall was maintained
during experimentation. Fig. 6 shows the levels of the anti-in-
ﬂammatory cytokines (NK-κB, IL-6, IL-10 and IL-1β) and inﬂammatory
chemokines (MCP-1, CXCL 10 and IL-8). Dosing with Symprove did not
alter the levels of NF-κB or IL-1β, but increased the levels of IL-6 and IL-
10 and decreased the levels of MCP-1, CXCL 10 and IL-8.
4. Discussion
The data reported here show that the probiotic species in Symprove
are capable of surviving the challenges of oral delivery under simulated
human conditions. Exposure to stomach acid for 45min and small-in-
testinal juice for 3 h did not signiﬁcantly reduce viable bacterial num-
bers (99.3% viability), a result that is in agreement with a previous in-
vitro stomach acid-tolerance and growth test (Fredua-Agyeman and
Gaisford, 2015). The primary factor in this stability is probably the fact
that the bacteria are suspended in an aqueous wort, rather than in a
freeze-dried compact/sachet or an oil-in-water emulsion (such as a
yoghurt); in-vivo, consumption of water does not trigger production of
stomach acid (which is primarily secreted to facilitate digestion of
proteins by denaturing them and activating pepsinogen by converting it
to pepsin (Smith and Morton, 2010; Wang et al., 2015)). Indeed, in-
gestion of appreciable volumes of water will dilute gastric juice, raising
local pH. Without fat, the stomach will empty water into the small in-
testine rapidly (the half-emptying time in humans is 13 ± 1min
(Mudie et al., 2014)), where local pH rises again (the small intestine pH
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Fig. 3. Average SCFA and lactate concentrations ± sd (n= 3) in the luminal compartments of the proximal and distal colon of the three donors for the donor control
samples (C) and following 1week (T1), 2 weeks (T2) and 3weeks (T3) daily dosing with Symprove. Lactate (top left), acetate (top right), propionate (bottom left) and
butyrate (bottom right). Results that are of statistical signiﬁcance compared with the control are indicated with * (P < 0.05).
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2008)). Lactobacilli have been shown to have appreciable acid-toler-
ance; for instance, L. acidophilus strains remain viable at pH 3.5 (Chou
and Weimer, 1999) while L. rhamnosus strains can remain viable for
several hours at pH 3 (Succi et al., 2005). When fat is a component of
the ingested foodstuﬀ, water empties at the same rate but the fat is
retained for a longer period (Chang et al., 1968). When glucose is
present above 6% w/v, gastric emptying is further delayed (Shi et al.,
2017).
Following transit through the upper GIT, three of the probiotic
bacteria (L. plantarum, L. rhamnosus and E. faecium) were able to es-
tablish, colonise and proliferate in the luminal and mucosal compart-
ments of the proximal and distal colon while L. acidophilus was able to
proliferate in the proximal lumen. Importantly, the data show that three
of the probiotic species were able to colonise the mucosal layer; this
suggests that in-vivo consumption of Symprove would lead to coloni-
sation of the gut by the probiotic species, rather than the luminal
numbers rising transiently, which helps to explain the positive, long-
term eﬀects seen during clinical studies (Sisson et al., 2014; Kvasnovsky
et al., 2017). Proliferation occurred despite the existence of an estab-
lished, and vibrant, microbiota, suggesting that the probiotic species
were not out-competed by the commensal bacteria for nutrients. Once
established, the probiotics had a positive inﬂuence; the principal eﬀect
was caused through an increase in lactate concentration. Cross-feeding
interactions from this substrate encouraged growth of commensal gut
bacteria, particularly those of the Firmicutes phyla, leading to increased
SCFA levels.
Changes in composition of the microbiota was seen for all donors,
although the speciﬁc changes varied, reﬂecting both the complexity and
diversity of human gut ﬂora. Broad changes in the gut microbiota have
been linked with gut disease; for instance, reduced levels of Firmicutes
and Actinobacteria are typically seen in IBS (Rajilic-Stojanovic et al.,
2011; Simren et al., 2013; Jalanka-Tuovinen et al., 2014; Distrutti et al.,
2016) while reduced levels of Firmicutes and increased levels of Pro-
teobacteria are typically seen in IBD (Matsuoka and Kanai, 2015).
As well as being produced by the Lactobacillus spp. in Symprove,
numbers of biﬁdobacteria were also seen to increase and these are
known to be lactate-producing (De Vuyst et al., 2014). This raises the
question of why biﬁdobacteria were stimulated to grow. One possibility
is that the wort used to produce and suspend the probiotic bacteria in
Symprove is itself a nutrient source for biﬁdobacteria, since it contains
germinated barley extracts. Untreated barley has been shown to in-
crease Biﬁdobacterium spp. and Lactobacillus spp., as well as increase
butyrate concentrations, in growing pigs (Moen et al., 2016) and in rats
fed low-fat diets (Zhong et al., 2015), while xylooligosaccharides from
barley have been shown to increase Lactobacillus spp. in simulated GIT
conditions (Gullón et al., 2014). The increase in biﬁdobacteria numbers
would in itself have a beneﬁcial impact on general health; for instance,
consumption of B. biﬁdum for 4 weeks modulated the microbiota in
healthy adults, reducing the numbers of Prevotellaceae and Prevotella,
increasing the numbers of Ruminococcaceae and Rikenellaceae and
raising butyrate concentrations (Gargari et al., 2016).
While acetate levels remained relatively constant throughout the
control and dosing periods, raised concentrations of acetate were sug-
gested by the increased proportion of acetate-producing bacteria (biﬁ-
dobacteria, bacteroidetes and acetogenic bacteria), but since measured
acetate concentrations always reﬂect the net diﬀerence between pro-
duction and consumption, overall levels were not signiﬁcantly in-
creased.
Conversely, concentrations of butyrate were signiﬁcantly higher,
because this is the end-point of fermentation; in-vivo, the majority of
butyrate is utilized by colonocytes (Hamer et al., 2008) but since these
are not present in the in-vitro gut model, butyrate accumulates in the
luminal medium. Since dysbiosis in UC patients has been linked to a
reduction in butyrate-producing species (Machiels et al., 2014), the
increase in butyrate seen here might confer a positive clinical eﬀect.
Given the numerous positive eﬀects of butyrate on human health, many
attempts have been made to formulate butyrate supplements; un-
fortunately, butyrate has a strongly unpleasant odour (Bedford and
Gong, 2018) and is largely absorbed in the upper GIT (Pituch et al.,
2013) and formulation of sodium butyrate in coated pellets proved
unsuccessful in modulating gut function in rats (Tuleu et al., 2001). The
data presented here suggest that a properly formulated probiotic sup-
plement may be a better approach, stimulating the existing microbiota
to produce butyrate rather than supplying it as a dietary supplement.
Since many gut conditions are diseases of inﬂammation, the eﬀect of
probiotics on modulating inﬂammatory responses is a critical factor in
their clinical eﬀectiveness. Here, the in-vitro cell culture model showed
no degradation in the integrity of the epithelial barrier, as well as re-
duced markers of inﬂammation, when exposed to SHIME media fol-
lowing dosing with Symprove. Levels of the anti-inﬂammatory cyto-
kines NK-κB and IL-1β were unchanged, while IL-6 was increased and
IL-10 was signiﬁcantly increased. Concomitantly, levels of the in-
ﬂammatory chemokines MCP-1, CXCL 10 and IL-8 were reduced. These
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Fig. 4. Average total BCFA (top) and ammonium (bottom) concentrations ± sd
(n=3) in the proximal and distal colon of the three donors for the donor
control samples and following 3 weeks daily dosing with Symprove.
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calprotectin levels were reduced in diverticular disease (Kvasnovsky
et al., 2017) and IBS (Sisson et al., 2014).
5. Summary
The data show that when a probiotic suspension is formulated in
such a way as to address the challenges of oral delivery in humans, then
viable probiotic species can be delivered to the gut. Once there, the
bacteria can inﬁltrate, colonise and proliferate in the luminal and
mucosal compartments. It is important to remember that the cell cul-
ture model is exposed to M-SHIME media, not the individual probiotic
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Fig. 5. Abundance (%) of the dominant phyla in the luminal (A) and mucosal (B) compartments of the proximal (PC) and distal (DC) colons at the end of the control
(C) and treatment (T) periods for three human donors (n= 1).
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Fig. 6. Eﬀect of SHIME samples (control and after dosing with Symprove) on the secretion of (A) anti-inﬂammatory cytokines (NF-κB, IL-6, IL-10 and IL-1β) and (B)
inﬂammatory chemokines (MCP-1, CXCL 10 and IL-8). Results that are of statistical signiﬁcance compared with the control are indicated with * (P < 0.05) and **
(P < 0.01).
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modulating the immune response. This is a critical distinction; the
World Health Organisation deﬁnition, which requires probiotics to
“confer a health beneﬁt on the host” (Hill et al., 2014), is often inter-
preted as meaning it must be demonstrated that the probiotic species
itself must by some metabolic mechanism cause a positive eﬀect in-vivo.
The data presented here clearly suggest that in fact integration and
colonisation of the probiotic species within the existing microbiota, and
the generation of a utilizable nutrient (lactate), stimulates growth of the
largely beneﬁcial phyla meaning that it is the rebalancing of bacterial
families that confers health beneﬁts to the host. This rebalancing eﬀect
is seen here even though the microbiota were obtained from three
healthy donors; since many gut diseases, as noted above, are linked to
dysbiosis it seems likely that the mechanism of rebalancing is the major
cause of improvement in clinical symptoms, rather than any eﬀect from
an individual probiotic species. It is notable also the data show no
negative inﬂuences on gut health.
Previous work (Fredua-Agyeman et al., 2017) has shown that Lac-
tobacillus spp. and Biﬁdobacterium spp. can exert anti-pathogenic action
against Clostridium diﬃcile. Thus, delivery of these probiotic species
may oﬀer an alternative treatment option for patients with recurrent
gut infections, before more radical measures such as fecal microbiota
transplant (Petrof and Khoruts, 2014).
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